Telomir Pharmaceuticals, Inc. · NASDAQ:TELO
Telomir Pharmaceuticals — Investor Presentation (July 2026)
25 slides from Telomir Pharmaceuticals's investor presentation, July 2026
Slide 1: Oral Epigenetic Therapy for Triple-Negative Breast Cancer (TNBC)
NASDAQ: TELO Oral Epigenetic Therapy for Triple-Negative Breast Cancer (TNBC) FDA IND CLEARED Phase 1/2 Ready July 2026 Telomir Pharmaceuticals, Inc.
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "can," "could," "wou
Slide 3: Why Telomir-Zn
Why Telomir-Zn A differentiated oncology program entering the clinic NOVEL MECHANISM CLINICAL CATALYST UNMET NEED BROAD ONCOLOGY POTENTIAL Oral Epigenetic IND Cleared by FDA for TNBC Remains a High Beyond TNBC Reprogramming via Metal Telomir-Zn in TNBC Unmet Need Setting Modulation Telomir-Zn is an
Slide 4: Triple-Negative Breast Cancer: A Significant Unmet Medical Need
Triple-Negative Breast Cancer No estrogen receptor. No HER2 TNBC Represents a Significant Unmet Medical Need overexpression. Limited targeted treatment options for most patients. Genomically Aggressive Disease Biology Complex Multi-Billion TNBC lacks a single Global TNBC ~10-15% Characterized by ear
Slide 5: Telomir-Zn: Epigenetic Reprogramming via Metal Homeostasis
Telomir-Zn: Epigenetic Reprogramming via Metal Homeostasis MECHANISM WHAT MAKES IT DIFFERENT REGULATORY STATUS Telomir-Zn modulates intracellular Rather than targeting a single metal homeostasis, including iron epigenetic enzyme, Telomir-Zn is FDA IND and copper, to influence iron- dependent epigene
Slide 6: Mechanism of Action: Epigenetic Modulation via Metal Homeostasis
Mechanism of Action: Epigenetic Modulation via Metal Homeostasis Inside the Cell Telomir-Zn is Telomir-Zn Iron (Fe) Telomir-Fe Zinc (Zn) designed to Telomir-Zn chelates excess intracellular iron (Fe2+), releasing zinc ions modulate intracellular metal homeostasis, influencing iron- dependent Outside
Slide 7: Broad Preclinical Anti-Tumor Activity Across Multiple Tumor Types
Broad Preclinical Anti-Tumor Activity Across Multiple Tumor Types Triple-Negative Breast Cancer Prostate Cancer Demonstrated anti-tumor activity across multiple TNBC Single-agent anti-tumor activity demonstrated in PC-3 models, including paclitaxel-resistant HCC1806 xenografts. prostate cancer xenog
Slide 8: Iron Rescue Demonstrates Iron-Dependent Activity
Iron Rescue Demonstrates Iron-Dependent Activity Key Takeaways •FeCl₂ partially rescued Telomir-Zn-induced loss of cell viability. •FeCl₂ shifted the IC₅₀ from ~1.5 μM to ~31 μM (~20- fold). Telomir-Zn Cell Line Used Cancer Type IC50 (µM) •These findings support an iron-dependent mechanism of action
Slide 9: Oral Telomir-Zn Reduces Tumor Growth in PC-3 Xenografts
Oral Telomir-Zn Reduces Tumor Growth in PC-3 Xenografts STUDY DESIGN •PC-3 androgen-independent prostate xenograft •Daily oral dosing for 21 days •Vehicle and active comparator controls KEY RESULTS 10 mg/kg Statistically significant tumor suppression from Day 10 (p<0.05) — earlier onset, sustained t
Slide 10: Telomir-Zn Reverses DNA Hypermethylation of Key Tumor-Suppressor Genes In Vivo
Telomir-Zn Reverses DNA Hypermethylation of Key Tumor-Suppressor Genes In Vivo WHY THIS MATTERS Untreated tumors progressively silence tumor-suppressor genes through promoter hypermethylation. Telomir-Zn reversed this silencing in vivo in a dose-dependent manner. These findings provide mechanistic e
Slide 11: Intellectual Property: Strong Global IP Position With Exclusive Worldwide Rights
Intellectual Property: Strong Global IP Position With Exclusive Worldwide Rights PATENT ESTATE EXCLUSIVITY DEVELOPMENT READINESS • Published PCT application • Exclusive worldwide rights • IND-cleared oncology (WO2024/191676 A1). to develop and program. commercialize Telomir-Zn • Patent estate includ
Slide 12: FDA IND Cleared. Phase 1/2 Ready.
FDA IND Cleared. Phase 1/2 Ready. 3+3 Simon 2- Top Centers Secondary Stage Endpoints Dose Escalation Design ORR Primary Endpoint Lead Clinical Site Duration of Response (Ph 1) for Oral, once-daily (Ph 2) Established with Top (DoR), Progression-Free monotherapy Cancer Center and Survival (PFS), and E
Slide 13: Focused Clinical Strategy
Focused Clinical Strategy Telomir-Zn is a focused clinical-stage oncology program for Triple- Negative Breast Cancer (TNBC). Completed GLP safety package, FDA IND clearance, and exclusive worldwide rights position the program for Phase 1/2 clinical development. Focused Clinical Strategy subject to r
Slide 14: Clinical Development Milestones
Clinical Development Milestones FDA IND FDA Phase 1/2 First Patient Submission Clearance Initiation Enrollment Completed Completed Subject to operational Following site activation readiness and site activation FDA IND submission IND clearance Planned Phase 1 dose Enrollment will begin completed foll
Slide 15: A Mechanistically Distinct Approach to Epigenetic Oncology
A Mechanistically Distinct Approach to Epigenetic Oncology Attribute Telomir-Zn Direct KDM Inhibitors Iron Chelators (DFO) PD-L1 Inhibitors Metal-mediated Mechanism epigenetic modulation Direct enzyme inhibition Systemic iron depletion Immune checkpoint Broad KDM modulation Selectivity with minimal
Slide 16: Clinical Stage Oncology Program
Positioned for Clinical Execution Clinical Stage Clinical Outlook Oncology Program FDA IND clearance establishes Telomir-Zn as a clinical-stage oncology program. The completed GLP safety package and Phase 1/2 protocol provide the foundation for advancing into clinical evaluation in triple-negative b
Slide 17: Leadership Team & Scientific Advisors
Leadership Team & Scientific Advisors Chief Executive Officer & Chief Scientific Advisor Chief Financial Officer Scientific Advisor Executive Chairman 40+ years of drug discovery and 20+ years of SEC reporting, public 30+ years leading CMC, regulatory Leads corporate strategy, financing, translation
Slide 18: Telomir Pharmaceuticals, Inc.
Oral Epigenetic Therapy for Triple-Negative Breast Cancer FDA IND Cleared Telomir Pharmaceuticals, Inc. NASDAQ: TELO telomirpharma.com This presentation is for informational purposes only and does not constitute an offer to sell or solicitation of an offer to buy any securities. 17
Slide 19: Appendix
Appendix Supporting Preclinical Data Telomir Pharmaceuticals, Inc. NASDAQ: TELO 18
Slide 20: Preclinical Research: Cell Viability Across Cancer Types
Preclinical Research: Cell Viability Across Cancer Types Iron-dependent selectivity confirms mechanistic anti-cancer activity Cell Line Cancer Type Iron Dependency IC₅₀ (µM) Preclinical Research Significant anti-cancer activity across multiple cancer cell lines with HCC1806 TNBC (breast) Highest 0.8
Slide 21: Significant Anti-Cancer Activity in BT 549 Breast Cancer Model
Significant Anti-Cancer Activity in BT 549 Breast Cancer Model Zebrafish xenograft | Triple-negative breast cancer | Oral administration daily x3 days Primary Tumor Size & Metastasis Data (% vs Control) Study Design • BT549 human triple-negative breast cancer cells in zebrafish xenograft • Telomir-Z
Slide 22: Telomir-Zn Suppresses Tumor Growth & Metastasis
Telomir-Zn Suppresses Tumor Growth & Metastasis Zebrafish xenograft | Triple-negative breast cancer | Oral administration daily x3 days Study Design Primary Tumor Size & Metastasis Data (% vs Control) • HCC1806 chemo-resistant human triple-negative breast cancer cells in zebrafish xenograft • Telomi
Slide 23: Telomir-Zn Potently Inhibits Histone Demethylases (KDMs) — KDM2 and KDM6
Telomir-Zn Potently Inhibits Histone Demethylases (KDMs) — KDM2 and KDM6 Key epigenetic enzymes driving cancer growth, inflammation, and aging KDMs in Cancer Biology • KDMs remove methyl groups from histones — controlling which genes are active or silenced KDM2/KDM5/KDM6 Iron-Dependent Dose-Response
Slide 24: Telomir-Zn Potently Inhibits Histone Demethylases (KDM5s / JARID1)
Telomir-Zn Potently Inhibits Histone Demethylases 5 (KDM5s / JARID1) Epigenetic erasers silencing tumor-suppressor genes and driving cancer stem-cell survival JARID1 / KDM5 Family in Cancer KDM5 Inhibition • KDM5 enzymes erase activating H3K4me3 marks — silencing tumor-suppressor and differentiation
Slide 25: Preclinical Research Summary
Preclinical Research Summary Complete preclinical package supporting FDA IND clearance FDA IND Cleared GLP Safety Package Complete Clean Genetic Safety Profile No DLTs · No treatment-related AEs Non-mutagenic · Non-genotoxic · Non-neurotoxic Domain Main Characteristics Details Pharmacology Selective
Telomir Pharmaceuticals — Investor Presentation (July 2026) on 6ix